contribuci n de la disfunci n mitocondrial
play

Contribucin de la disfuncin mitocondrial al desarrollo de las complicaciones vasculares de la Diabetes Tipo 2 Mara Monsalve mpmonsalve@iib.uam.es Vascular complications of diabetes Diabetic retinopathy Leakage Loss of pericytes

0 downloads 2 Views 2,93 MB Size Report
  1. Contribución de la disfunción mitocondrial al desarrollo de las complicaciones vasculares de la Diabetes Tipo 2 María Monsalve mpmonsalve@iib.uam.es

  2. Vascular complications of diabetes

  3. Diabetic retinopathy Leakage Loss of pericytes Hemorrhages Tortuosity

  4. Clinical treatment, anti-VEGF -Inefective angiogenesis, -Vessels are tortuous, dilated, poorly perfused -Poor perycite coverage -Hemorragic -Tissular hypoxia

  5. Hyperglicemia Increases mitochondrial ROS production [gluc] 5mM 30mM PGC-1  PGC-1 a � I.Valle et al. , CvR, 2005 MitoSox S. Borniquel et al. , MCB, 2010

  6. Mitocondria, una fuente de ROS Cu-ZnSOD O 2.- H 2 O 2 ETC Intermembrane space H + H + H + O 2 .- CoQ C UC ATPasa P Iinner I F 1 Mitochondrial III IV NADH Membrane F 0 II NADPH DH O 2 H 2 O ADP ATP O 2 .- NADP + O 2 .- P i NADH FADH 2 H + H + GR Mitochondrial matrix GSH PGC-1  GSSG ROS MnSOD GPx ROS ANTIOXIDANT Production ANTIOXIDANT O 2.- H 2 O 2 H 2 O + O 2 PRODUCTION DEFENCES DEFENCES Physiopathologica ONOO - l conditions NADPH CAT NADP + TrxS 2 H 2 O + O 2 TrxR OXIDATIVE STRESS HOMEOSTASIS Fenton reaction Prx Cellular damage Signalling Trx(SH) 2 Diseases . OH Cell death Aging H 2 O

  7. PGC-1  , a modulator of mitochondrial ROS Glucose ATP ATP Glucose ROS ATP Glucose ROS PGC-1  PGC-1  ATP ATP Lipids ROS 160 Mitochondria PGC-1 � RNA-POL� II � 120 * % 80 TF � * 40 0 5 mM Gluc 30 mM Gluc 48 h treatment Control Ad- PGC- 1 Ad I.Valle et al. , CvR, 2005

  8. Perdida de recubrimiento pericítico y baja perfusión en ausencia de PGC-1  PGC-1  +/+ PGC-1! +/+ PGC-1 α +/+ PGC-1 α -/- Isolectin B4 NG2 SMA PGC-1  -/- PGC-1! -/- PGC-1 α +/+ PGC-1 α -/- PGC-1! +/+ PGC-1! -/- Isolectin B4 NG2 SMA PGC-1 a � +/+� PGC-1 a � *� -/-� Mean Intensity Area 35 18 40 10 16 30 8 30 14 a.u. % ! Area (%) Area (%) *� 25 % 12 6 % ! %� 20 20 10 4 8 15 *� 10 6 2 10 4 0 0 5 2 PGC-1 ! ! "#"! PGC-1 ! ! $ PGC-1 ! ! PGC-1 ! ! $ #$ ! "#"! #$ ! 0 0 Iso B4 SMA NG2/edge NG2/center N. García-Quintans et al. , Angiogénesis, 2016

  9. OIR induce la translocación de VE-Cadherin al citosol en ausencia de PGC-1  PGC-1 α +/+ PGC-1 α -/- 1E+11 OIR 9E+10 Membrane 8E+10 Cytosol 7E+10 6E+10 5E+10 4E+10 3E+10 *� 2E+10 1E+10 0 PGC-1 a � PGC-1 a � +/+� -/-� N. García-Quintans et al. , Angiogénesis, 2016

  10. Torduosidad y hemorragias en ausencia de PGC-1  PGC- PGC- PGC-1 α +/+ PGC-1 α -/- 1 α +/+ 1 α -/- Primary plexus D SD* PGC-1 a +/+ PGC-1 a -/- PGC-1 a +/+ PGC-1 a -/- PGC-1 a +/+ PGC-1 a -/- PGC-1 α +/+ PGC-1 α -/- Number of Hemorrhages % ! 80 25! Hemorrhage Area % ! 20! 60 15! 40 10! 20 5! 0 0! PGC-1 ! ! "#"! PGC-1 ! ! PGC-1 ! ! "#"! PGC-1 ! ! $ #$ ! $ #$ ! N. García-Quintans et al. , Angiogénesis, 2016

  11. Antioxidant treatment improves vascular stability OIR PGC-1 α -/- OIR PGC-1 α -/- V � Iso B4 NG2 EUK-189 Primary plexus Inner plexus PGC-1 a � +/+� PGC-1 a � -/-� Area (%) Vehicle EUK-189 Vehicle EUK-189 Primary plexus *� D SD* Iso B4 NG2 SMA Vehicle EUK-189 Vehicle EUK-189 N. García-Quintans et al. , Angiogénesis, 2016

  12. El tratamiento con antioxidantes no recupera la polaridad de las células tip PGC-1 α +/+ PGC-1 α -/- PGC-1 α +/+ Iso B4 PGC-1 α -/- EUK-189 V Iso B4 N. García-Quintans et al. , Angiogénesis, 2016

  13. IPC induces perivascular fibrosis in the absence of PGC-1 α C. Sánchez-Ramos et al. , ARS, 2017

  14. MEMORY Prevalence of mitochondrial dysfunction in T2D -The mtDNA

  15. ¿Quiénes somos? El lab: Ignacio Prieto Raquel García Principales colaboradores: Gaurang Patel Ramazan Yildiz Ángela M Valverde (IIBm) Sebastian Cerdán (IIBm) Isabel Cordova Susana Cadenas (CBMSO) Miriam Granado (UAM) Jose Carlos Martinez Santamaría

Recommend Documents


atypical presentation of disseminated intravascular
Atypical Presentation of Disseminated

JOP. J Pancreas (Online) 2015 Mar 20; 16(2):195-197. CASE REPORT Atypical

miragen therapeutics
miRagen Therapeutics NASDAQ: MGEN

Restoring Biological Harmony for Patients with Debilitating Disease Restoring

philip l ho md urologic oncology fellow the university of
Philip L. Ho, MD Urologic Oncology

Stat3 Transgenic Mice as a Model for Human Basal Subtype of Invasive Bladder

hele shaw limit for a model of tumor growth with nutrients
Hele-Shaw limit for a model of tumor

Hele-Shaw limit for a model of tumor growth with nutrients Noemi David (LJLL,

repliderm inc repliderm inc
REPLIDERM Inc. REPLIDERM Inc. GROUP

REPLIDERM Inc. REPLIDERM Inc. GROUP 8 Tiwalade Ashaye, Joseph Azzarello,

company presentation may 2016 forward looking statement
Company Presentation - May 2016

Company Presentation - May 2016 Forward looking Statement This presentation

to fight cancer
TO FIGHT CANCER 1Q 2020 7 May 2020

ACTIVATING THE PATIENTS IMMUNE SYSTEM TO FIGHT CANCER 1Q 2020 7 May 2020

blu 285 a potent and highly selective inhibitor designed
BLU-285: A potent and highly selective

BLU-285: A potent and highly selective inhibitor designed to target

research symposium
RESEARCH SYMPOSIUM Tuesday 23 October

BACHELOR OF BIOMEDICAL SCIENCE (HONOURS) RESEARCH SYMPOSIUM Tuesday 23

cancer associated thrombosis an update
Cancer Associated Thrombosis: An Update

Cancer Associated Thrombosis: An Update Professor Anthony Maraveyas Hull

port al hype rt e nsi on
PORT AL HYPE RT E NSI ON An I

11/26/2018 PORT AL HYPE RT E NSI ON An I ntro duc tio n to the

and fractional flow reserve
and Fractional Flow Reserve Aichi

TCTAP 2019 Effect of Breath Holding on Coronary Stenosis Sandwiched Between